Creatine and coenzyme Q10 in the treatment of ALS

Amyotrophic Lateral Sclerosis

Volumn 1, Issue SUPPL. 4, 2000, Pages 17-20

  Strong, Michael J ^a   Pattee, Gary L ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CREATINE; DRUG DERIVATIVE; UBIDECARENONE; UBIQUINONE;

AMYOTROPHIC LATERAL SCLEROSIS; HUMAN; METABOLISM; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANTS; CREATINE; HUMANS; UBIQUINONE;

EID: 0034575147     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/14660820050515665     Document Type: Article

References (35)

1. O'Gorman E, Beutner G, Wallimann T, Brdiczka D. Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim Biophys Acta 1996; 1276: 161-170. (Pubitemid 26308733)
2. Siklos L, Englehardt J, Harati Y, Smith RG, Joo F, Appel SH. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 203-216. (Pubitemid 26071571)
3. Masui Y, Mozai T, Kakehi K. Functional and morphometric study of the liver in motor neuron disease. J Neurol 1985; 232: 15-19. (Pubitemid 15076981)
4. Nakano Y, Hirayama K, Terao K. Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch Neurol 1987; 44: 103-106. (Pubitemid 17087619)
5. Wiedemann FR, Winkler K, Kuznetsov A, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J Neurol Sci 1998; 156: 65-72. (Pubitemid 28141041)
6. Fujita K, Yamauchi M, Shibayama K et al. Decreased cytochrome c oxidase activity but unchanged superoxide dismutase and glutathione peroxidase activities in the spinal cords of patients with amyotrophic lateral sclerosis. J Neurosci Res 1996; 45: 276-281. (Pubitemid 26322816)
7. Bowling AC, Schulz JB, Brown RH, Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem 1993; 61: 2322-2325. (Pubitemid 23354097)
8. Browne SE, Bowling AC, Baik MJ, Gurney ME, Brown RH, Jr, Beal FM. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J Neurochem 1998; 71: 281-287. (Pubitemid 28292560)
9. Swerdlow RH, Parks JK, Cassarino DS, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol 1998; 15 3:135-142. (Pubitemid 28452305)
10. Curti D, Malaspina A, Facchetti G, et al. Amyotrophic lateral sclerosis: oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology 1996; 47: 1060-1064.
11. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997; 69: 2064-2074. (Pubitemid 27452754)
12. Shaw PJ, Ince PG, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 1995; 38: 691-695.
13. Bruijn LI, Becher MW, Lee MK, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-338. (Pubitemid 27111114)
14. Dal Canto MC, Gurney ME. Development of central nervous system pathology in a murine transgenic model of amyotrophic lateral sclerosis. Am J Pathol 1994; 145: 1271-1280. (Pubitemid 24984196)
15. Dal Canto MC, Gurney ME. Neuropatholigcal changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (ALS). Brain Res 1995; 676: 25-40.
16. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing mutant SOD1. J Neurosci 1998; 18: 3241-3250. (Pubitemid 28186017)
17. Mourelatos Z, Gonatas NK, Stieber A, Gurney ME, Dal Canto MC. The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Proc Natl Acad Sci USA 1996; 93: 5472-5477. (Pubitemid 26159474)
18. Wong PC, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motorneuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105-1116.
19. Bogdanov MB, Ramos LE, Xu Z, Beal FM. Elevated 'hydroxyl radical' generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 1998; 71: 1321-1324. (Pubitemid 28390288)
20. Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH, Jr, Beal FM. Metabolic dysfunction in familial, but not sproadic, amyotrophic lateral sclerosis. J Neurochem 1998; 71: 281-287. (Pubitemid 28292560)
21. Andrus PK, Fleck TJ, Gurney ME, Hall ED. Proetin oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1998; 71: 2041-2048. (Pubitemid 28491560)
22. Carri MT, Ferri A, Battistoni A, Famhy L, Gabbinaelli R, Poccia F, Rotilio G. Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Letts 1997; 414: 365-368. (Pubitemid 27389396)
23. Dugan LL, Turetsky DM, Du C, et al. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci USA 1997; 94: 9434-9439. (Pubitemid 27357847)
24. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5: 347-350. (Pubitemid 29124375)
25. Mizuno M, Quistorff B, Theorell H, Theorell M, Chance B. Effects of oral supplementation of coenzyme Q10 on 31PNMR detected skeletal muscle energy metabolism in middleaged post-polio subjects and normal volunteers. Mol Aspects Med 1997; 18: S291-S298.
26. Xu CJ, Klunk WE, Kanfer JN, Xiong Q, Miller G, Pettegrew JW. Phosphocreatine-dependent glutamate uptake by synaptic vesicles. J Biol Chem 1996; 271: 13435-13440.
27. O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Letts 1997; 414: 253-257. (Pubitemid 27389373)
28. Kernec F, Le Tallec N, Nadal L, Bégué J-M, Le Rumeur E. Phosphocreatine synthesis by isolated rat skeletal muscle mitochondria is not dependant upon external ADO: a 31P NMR study. Biochem Biophys Res Comm 1996; 225: 819-825. (Pubitemid 26319189)
29. Whittingham TS, Lipton P. Cerebral synaptic transmission curing anoxia is protected by creatine. J Neurochem 1981; 37: 1618-1621. (Pubitemid 12219012)
30. Carter AJ, Müller RE, Pschorn U, Stransky W. Preincubation with creatine enhances levels of creatine phosphate and prevents anoxic damage in rat hippocampal slices. J Neurochem 1995; 64: 2691-2699.
31. Matthews RT, Yang L, Jenkins BG, et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998; 18: 156-163. (Pubitemid 28046777)
32. Harris RC, Söderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of neormal subjects by creatine supplementation. Clin Sci 1992; 83: 367-374.
33. Clarkson PM, Rawson ES. Nutritional supplements to increase muscle mass. Crit Rev Food Sci Nutr 1999; 39: 317-328. (Pubitemid 129549614)
34. Felber S, Skladal D, Wyss M, Kremser C, Koller A, Sperl W. Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study. Neurol Res 2000; 22: 145-150. (Pubitemid 30180791)
35. Walter MC, Lochmuller H, Reilich P et al. Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study. Neurology 2000; 54: 1848-1850. (Pubitemid 30428416)